

Supplementary Fig1







	+EGF	-EGF
KRAS wild-type organoid		
KRAS mutant organoid		

Figure S1: Brightfield images representative of organoid cultures (upper: KRAS wild-type, lower: KRAS mutant) in medium with EGF removed at day 5.

Supplementary Fig2

a Fucose binding Lectin



Supplementary Fig2




Fig S2: Analysis of lectin intensity and FUT6 expression by site of KRAS mutation

Data are shown as means \pm SD. Student's t test. **p < 0.001. *p < 0.05.

- a) Reactivity of fucose-binding lectin signal intensities from lectin microarray for KRAS wild -type (WT), Q61L, G12V, and G12D(a-1). Comparison of the intensities with WT and G12V, WT and G12D, respectively (a-2).
- b) Expression of the FUT6 mRNA from RNA seq for KRAS wild -type (WT), Q61L, G12V, and G12D (b-1). Comparison of the expression with WT and G12V, WT and G12D, respectively (b-2).
- c) FUT6 mRNA expression from RNA seq and reactivity of fucose-binding lectin signal intensities from lectin microarray of organoids from KRAS wild-type (WT) and preoperative treated (Neoadjuvant) and untreated (No treat) patients.

Supplementary Fig3




Figure S3: Comparison of glycosyltransferases (mannnosyltransferase, galactosyltransferase, sialyltransferase) expression based on the result of RNA-seq between KRAS mutant and KRAS wild-type organoids